Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
341 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Currently Recruiting (2)

Medical Condition

  • Show all (126)
  • Allergy, Asthma, & Immunology (1)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (6)
  • Bone & Muscle (1)
  • Cancer (74)
    • (-) Bladder Cancer (1)
    • Brain Cancer (2)
    • Breast Cancer (1)
    • Head and Neck Cancer (1)
    • Kidney Cancer (1)
    • Leukemia (2)
    • Lung Cancer (1)
    • Lymphoma (6)
    • Pancreatic Cancer (1)
    • (-) Prostate Cancer (1)
    • Sarcoma (1)
    • Skin Cancer (30)
    • Solid Tumors (3)
  • COVID-19 (Coronavirus) (2)
  • Diabetes (1)
  • Gastrointestinal and Digestive Diseases (1)
  • Hair and Skin Disorders (2)
  • Healthy Volunteers (12)
  • Heart Disease (3)
  • Infectious Disease (1)
  • Kidney Disease (1)
  • Lung Disease (5)
  • Neurological Disorders (4)
  • Obstetrics & Gynecology (2)
  • Pediatrics (4)
  • Psychiatric Disorders (1)
  • Rehabilitation (1)
  • Transplant (2)
  • Vascular Conditions (1)
Displaying 1 - 2 of 2

NeoSTOP-IT: Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer

Condition: Cancer / Bladder Cancer
Investigator: Alexander Wei, MD
Status: Currently Recruiting
The purpose of this study is for patients with a localized bladder cancer called muscle-invasive bladder cancer. Muscle-invasive bladder cancer is usually treated with a combination of chemotherapy and surgery. This surgery removes the entire bladder, which changes how they urinate for the rest of their life. Some patients will have a small opening in the…
Read More

Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

Condition: Cancer / Prostate Cancer
Investigator: Mark Stein, MD
Status: Currently Recruiting
The purpose of this study is to determine the safety, tolerability (how your body reacts to the drug) and effectiveness of REGN5678 which will be given alone first and then be given in combination with cemiplimab. Neither REGN5678 nor Cemiplimab is FDA-approved to treat your type of cancer. Cemiplimab is approved by the FDA for the treatment of certain…
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science